Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis? - Schreiner, P.; Greuter, T.; Tatu, A.; Keller, D. I.; Straumann, A.; Biedermann, L. (Dysphagia, 2021)
Since most pharmacological treatments in case of esophageal food impaction (EFI) are unsuccessful, an endoscopy is usually required to resolve EFI. We present the first results of a budesonide orodispersible tablet (BOT) as a medical treatment option before endoscopy. We evaluated all patients with a suspected EFI to receive BOT before emergent endoscopy at a tertiary hospital between March 2019 and June 2020. A total of eight patients received BOT before endoscopy. Mean age was 50.1 years and 87.5% were male. In 38% (3/8) of patients the EFI resolved without endoscopic intervention. No adverse events occurred. After endoscopy, a diagnosis of EoE was established in 75%. This case series demonstrate the potential of BOT as medical rescue therapy in case of EFI.
Keywords: journalArticle; *Deglutition Disorders/diagnosis/drug therapy/etiology; *Eosinophilic Esophagitis/complications/diagnosis/drug therapy; AG, Switzerland, Esocap AG, Switzerland, Sanofi-Aventis AG, Switzerland and; Budesonide orodispersible tablet; Calypso Biotech SA; Deglutition; Deglutition disorders; Emergency Service, Hospital; Enteritis; Eosinophilia; Esophageal food impaction; Female; GSK, Receptos-Celgene and Regeneron-Sanofi. LB received consulting fees and/or; Gastritis; GmbH and Vifor, and an unrestricted research grant from Novartis. AT has no; Humans; Male; Middle Aged; Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma; Steroids/therapeutic use; conflict of interest. DIK has no conflict of interest. AS reports receiving; consulting fees from Allakos, AstraZeneca, EsoCap, Dr. Falk Pharma, Gossamer,; speaker fees and/or research grants from Dr. Falk Pharma, GmbH, Germany, Vifor; support from Falk, UCB and Pfizer. TG has consulting contracts with